Mechanisms of Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Ritonavir‐Enhanced Tipranavir

  title={Mechanisms of Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Ritonavir‐Enhanced Tipranavir},
  author={M. Vourvahis and A. Kashuba},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  • M. Vourvahis, A. Kashuba
  • Published 2007
  • Medicine
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
  • Tipranavir is a nonpeptidic protease inhibitor that has activity against human immunodeficiency virus strains resistant to multiple protease inhibitors. Tipranavir 500 mg is coadministered with ritonavir 200 mg. Tipranavir is metabolized by cytochrome P450 (CYP) 3A and, when combined with ritonavir in vitro, causes inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A in addition to induction of glucuronidase and the drug transporter P‐glycoprotein. As a result, drug‐drug interactions… CONTINUE READING
    45 Citations

    Paper Mentions

    Blog Post
    Metabolism-Mediated Drug Interactions Associated with Ritonavir-Boosted Tipranavir in Mice
    • 21
    • PDF
    Tipranavir: a review of its use in the management of HIV infection.
    • 30
    • Highly Influenced
    Drug interactions with antiretrovirals and warfarin
    • 29
    Drug Interactions with New and Investigational Antiretrovirals
    • 51
    • PDF
    Induction Effects of Ritonavir: Implications for Drug Interactions
    • 139
    Toxicity of HIV protease inhibitors: clinical considerations
    • 32


    Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir
    • 88
    Tipranavir: A Protease Inhibitor From a New Class With Distinct Antiviral Activity
    • P. Yeni
    • Medicine
    • Journal of acquired immune deficiency syndromes
    • 2003
    • 34
    Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.
    • 119
    Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.
    • 52
    • PDF
    The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.
    • 126
    • PDF
    Management of drug‐to‐drug interactions between cyclosporine A and the protease‐inhibitor lopinavir/ritonavir in liver‐transplanted HIV‐infected patients
    • M. Vogel, E. Voigt, +6 authors U. Spengler
    • Medicine
    • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
    • 2004
    • 87
    The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
    • 97
    • PDF
    Tacrolimus and Lopinavir/Ritonavir Interaction in Liver Transplantation
    • 47